TMS for OCD: What It Targets, What the Evidence Shows, and What to Ask

TMS is an added treatment option for some adults with obsessive-compulsive disorder. It is not a cure, and its evidence is more mixed than a simple response-rate headline suggests.

Direct answer: TMS can help some adults with OCD when ERP and medication have not been enough. The FDA-authorized OCD protocol uses repeated magnetic pulses over a medial frontal target after a brief, personal symptom trigger. In the pivotal trial, average improvement beat sham in one planned analysis, but not in the full intention-to-treat analysis.

Key points

• OCD involves unwanted thoughts, images, or urges and repeated acts that cause distress or interfere with life. It is not a lack of willpower.
• OCD TMS uses a different target and treatment plan from the best-known depression TMS protocol.
• The formal device label says adults. The pivotal BrainsWay study enrolled people ages 22 to 68.
• The standard course is 29 sessions over six weeks. A brief, supervised symptom trigger comes before each treatment.
• The strongest trial result was positive in a modified analysis, but the full study-group analysis was not statistically significant. Remission was uncommon.
• FDA status is device-specific. A clinic should name its device, coil, protocol, and cleared use.

Zoom

OCD is more than a habit or a worry

Everyone has unwanted thoughts at times. Many people also check a lock twice or like things in a certain order. OCD is different. It can include obsessions, which are unwanted thoughts, images, or urges, and compulsions, which are repeated actions or mental rituals. These symptoms may take more than an hour a day, cause marked distress, or get in the way of school, work, sleep, relationships, or daily life. People often know the cycle is excessive, yet still feel driven to complete it.[1] For a fuller picture of the condition itself, see what OCD actually is.

OCD themes can involve harm, contamination, religion, sex, relationships, mistakes, or the need for certainty. A thought does not reveal a person’s character or intent. Shame can delay care, but clinicians who treat OCD are trained to hear these symptoms without judgment.

Before considering TMS, the diagnosis should be checked carefully. OCD can overlap with depression, tic disorders, trauma symptoms, psychosis, or autism-related routines. The right plan depends on what is causing the symptoms.

Where TMS may fit in treatment

Exposure and response prevention, or ERP, is a form of cognitive behavioral therapy with strong support for OCD. A person gradually faces a feared trigger while practicing a response other than the compulsion. Selective serotonin reuptake inhibitors, or SSRIs, and clomipramine can also help. A medication needs a fair trial before it is judged.[1,2] How ERP, medication, and TMS fit together in OCD care covers the order of treatment in more depth.

TMS is usually considered when well-delivered ERP, medication, or both have not helped enough, were not tolerated, or cannot be used. Its OCD label is adjunctive, which means added to care rather than automatically replacing it. In the pivotal study, participants stayed on their existing medication and/or psychotherapy at a stable level.[3,4]

Do not stop ERP or medication on your own when starting TMS. A prescriber and therapist can decide whether later changes are safe and sensible.

How OCD TMS works

What is established

A TMS coil rests against the scalp. A fast-changing magnetic field induces a small electrical current in nearby cortex. This is not surgery. Coil shape, location, pulse strength, timing, and session count all affect the dose.[3,4] The basics of coils, targets, and dose are explained in how TMS works and why the details matter.

OCD treatment focuses on medial frontal regions. The original BrainsWay protocol used an H7 coil positioned from a leg motor-threshold site to engage medial prefrontal and anterior cingulate-related cortex. Some later FDA-cleared systems use double-cone or figure-eight coils over the dorsomedial prefrontal cortex. By contrast, a common depression protocol targets the left dorsolateral prefrontal cortex, which is farther to the side. These protocols are not interchangeable.[3,8-11]

The supported idea

Research links OCD to several connected cortico-striato-thalamo-cortical, or CSTC, networks. They help the brain notice possible errors, choose actions, and shift behavior. Think of traffic that has trouble changing routes while an alarm demands attention. This picture is limited: there is no single OCD loop, and a scan cannot read a person’s thoughts.[7]

Researchers think repeated pulses may change how medial frontal cortex works with the wider network. Bringing up a symptom just before treatment may place the network in a symptom-related state when pulses arrive. That is a reasonable state-dependent treatment hypothesis, not proof that the trigger adds benefit.

What remains unknown

We do not know the exact change that helps an individual. “Deep TMS” does not mean precise, isolated stimulation of the anterior cingulate. No validated scan, brain-wave test, or symptom type can reliably predict response.[3,7]

What an FDA-authorized course involves

In 2018, FDA granted De Novo classification and marketing authorization to the BrainsWay Deep TMS System as an adjunct for adults with OCD. Later systems became FDA-cleared through the 510(k) substantial-equivalence pathway. This does not mean each system ran a new pivotal OCD trial.[3,4,8-11]

The original protocol measures resting motor threshold from a leg or foot muscle. This minimum output that produces a small muscle response helps set the dose. The coil is placed 4 cm in front of that site, and threshold is checked weekly.[4]

The treatment uses 20 pulses per second at 100% of the leg motor threshold. Each train lasts two seconds, followed by a 20-second pause. Fifty trains deliver 2,000 pulses in about 18 to 20 minutes. There are five weekday sessions in each of the first five weeks and four sessions in week six, for 29 sessions total. Setup and the symptom exercise make the full visit longer.[4,8]

The label says adults. The pivotal BrainsWay trial studied ages 22 to 68, which is not proof for every adult age. Later summaries list other comparison ranges. A clinic should check its exact device instructions.[4,10,11]

What symptom provocation means

Before each pivotal-trial session, a trained clinician used a personal trigger for up to five minutes. The goal was moderate distress, about 4 to 7 on a 10-point scale. A contamination fear might be activated by an image or thought. A checking fear might be activated by leaving a question unresolved. The plan should be agreed on, supervised, and stopped or adjusted if distress becomes unsafe.[4,5]

This trigger is not a full ERP session. ERP builds learning by facing fear and not doing the ritual. The TMS trigger brings up symptoms before pulses. A 2025 meta-analysis found that active TMS beat sham in OCD studies with and without provocation. Its estimated added effect was not significant, and direct comparisons were scarce. We cannot say provocation itself improves results.[6]

What the research shows

The pivotal trial

The main study was a randomized, double-blind, sham-controlled trial at 11 sites in the United States, Israel, and Canada. Of 100 people enrolled, one left before treatment. The full intention-to-treat, or ITT, group had 99 people: 48 active and 51 sham. Five ineligible people were identified before the blind was opened, leaving 94 in the modified ITT, or mITT, group.[4,5]

Symptoms were scored with the Yale-Brown Obsessive Compulsive Scale, or Y-BOCS. Scores range from 0 to 40, and lower is better. At week six, the adjusted average drop in the mITT group was 6.04 points with active treatment and 3.27 with sham. The 2.78-point difference met the statistical test, with p=.0127. This was the positive primary result.[4]

The full ITT result was less certain. The adjusted drop was 5.97 points with active treatment and 4.05 with sham. The 1.92-point difference was not significant, with p=.0988. The U.S.-only mITT difference was about 1.8 points and not significant. Outside the United States it was about 5.6 points and significant. Site, patient, delivery, or chance differences are possible, but the data do not choose an explanation.[4]

“Response” meant at least a 30% Y-BOCS reduction. Among mITT participants with a week-six score, 16 of 42 receiving active treatment responded, or 38.1%, versus 5 of 45 receiving sham, or 11.1%. In the full ITT observed analysis, the rates were 16 of 43, or 37.2%, and 9 of 49, or 18.4%. Every percentage needs its analysis and denominator.[4]

Remission was rare. Using Y-BOCS below 10, 2 of 42 active-treatment participants and 2 of 45 sham participants in the mITT group were in remission at week six. The trial therefore supports a chance of meaningful symptom improvement for some people, not an expectation that symptoms will disappear.[4]

Secondary outcomes followed a planned order to limit false positives. The first, the Sheehan Disability Scale, was not significant, so the testing hierarchy stopped. Later p values were not adjusted for multiple testing and are exploratory, not confirmed outcomes.[4]

At week 10, four weeks after treatment ended, the average mITT Y-BOCS change was still larger with active treatment. That follow-up is too short to answer how long benefit lasts, who needs maintenance, or what schedule should be used.[4]

Evidence for later cleared systems

The 2019 BrainsWay change kept the indication and core protocol.[12] MagVenture’s 2020 clearance used field testing, modeling, bench comparisons, and literature. Its summary says the device had no new pivotal trial. CloudTMS, later MagVenture configurations, and Nexstim also used predicate-based pathways without a new device-specific pivotal OCD efficacy trial in the cited summaries. Nexstim added MRI navigation but still uses a measured 4 cm offset from the leg motor site.[8-11]

This does not mean those devices are uncleared or ineffective. It means the evidence chain is different. The BrainsWay H7 system has the pivotal randomized trial in its own De Novo record. Later systems are FDA-cleared based on substantial equivalence, supported by technical testing and other evidence. A clinic should not present the original H7 response rate as if every cleared coil independently reproduced it in a large randomized OCD trial.

Safety and day-to-day burden

In the pivotal trial, at least one adverse event was reported by 73% of active-treatment participants and 69% of sham participants. Headache was reported by 37.5% with active treatment and 35.3% with sham. Other common problems included scalp or site pain, facial or jaw discomfort, muscle twitching, neck pain, and dizziness. Most were mild or moderate.[4]

One participant reported suicidal thoughts after two treatments and was hospitalized. The thoughts had started before study treatment, and investigators judged the event unrelated. No clear hearing loss was reported, but the study did not perform formal hearing tests. Hearing protection remains part of safe TMS practice.[4]

TMS can cause a seizure, although this is uncommon with a cleared protocol and proper screening. Tell the clinic about seizures, brain injury, head metal, implanted devices, medicine or substance changes, sleep loss, pregnancy, and hearing problems. Exact device instructions determine which implants or conditions are unsafe. Ask how the team handles pain, panic, or a trigger that becomes too strong.[3,4]

The time burden is real: 29 clinic visits in six weeks, plus travel and setup. Coverage rules, copays, and authorization requirements vary. Ask for a written estimate and for the clinic’s plan if sessions are missed.

Related TMS guides

• How TMS works: coils, targets, dose, schedule, and FDA status explained
• ERP, medication, and TMS: how OCD treatments fit together and what to verify before anyone says treatment resistant
• Types of OCD symptoms across ages
• TMS for depression: a different target and protocol, with its own evidence
• TMS for PTSD: the 2026 MeRT clearance and its limits

What we still do not know

• Which symptoms, brain measures, or clinical features reliably predict benefit.
• Whether symptom provocation adds benefit beyond the stimulation itself.
• How well the pivotal result generalizes across countries, ages, illness patterns, and routine clinics.
• Whether every FDA-cleared coil and positioning system produces the same clinical outcomes.
• How long improvement lasts beyond the short follow-up in the pivotal trial.
• Whether scheduled maintenance helps, and if so, which schedule is best.
• How OCD TMS compares head-to-head with expert ERP, medication changes, or combined care.

These gaps do not erase the positive mITT finding. They explain why the decision should include the full result, the negative analyses, burden, cost, and other treatment choices.

Questions to ask a TMS clinic

1. What is the exact manufacturer, model, coil, and FDA-cleared OCD indication you use?
2. Is your treatment plan the cleared 20 Hz, 2,000-pulse, 29-session protocol? If not, what is different and why?
3. How do you find the leg motor threshold and treatment position, and how often do you recheck them?
4. Who creates and supervises symptom provocation? How do you keep distress in a safe range?
5. How will TMS work with my ERP therapist and prescriber?
6. How do you measure progress with the Y-BOCS, and when will we decide whether to continue?
7. What adverse effects, implant restrictions, and seizure precautions apply to this device?
8. What happens after session 29? Is maintenance on-label, what supports it, and what will it cost?
9. Which outcome numbers do you quote, and are they mITT, full ITT, completer, or real-world results?

Patient FAQs

Does TMS cure OCD?

No. Some people have a meaningful drop in symptoms, some have little change, and remission was uncommon in the pivotal trial. A good goal is less time lost to OCD and more ability to use ERP skills, not a promise that every intrusive thought will stop.

Is OCD TMS the same as depression TMS?

No. Common protocols use different targets, coils, positioning methods, pulse patterns, and treatment plans. A device cleared for depression is not automatically cleared for OCD.

Is symptom provocation the same as ERP?

No. Provocation is a short, personal trigger before stimulation. ERP is a structured therapy that builds new learning by facing fears and changing the response. They may occur in the same care plan, but one does not replace the other.

Can I stop medication or ERP when I start?

Not on your own. The pivotal trial kept existing treatment stable. Sudden medication changes can cause symptoms or alter seizure risk. Plan changes with the clinicians who know your history.[4]

How many visits are there?

The cleared course uses 29 sessions over six weeks: five sessions each week for five weeks, then four in week six. A treatment itself takes about 18 to 20 minutes, but the visit is longer.

How soon would I know if it is helping?

Clinics usually track symptoms through the six-week course rather than judging one visit. Ask for a baseline Y-BOCS and planned repeat scores so that “better” has a shared meaning.

What does response mean?

In the pivotal study, response meant at least a 30% drop in Y-BOCS. It did not mean symptom-free. Ask for both your score change and the daily-life change that matters to you.

Who may need a different plan?

People with certain head or neck metal, implanted electronic devices, seizure risks, major medical changes, pregnancy, or severe distress during provocation need device-specific review. Adolescents also fall outside the adult OCD indication described here.[3,4]

A neutral next step

If OCD still causes major limits after a fair course of ERP, medication, or both, ask an OCD-trained clinician and a TMS clinician to review the case together. Bring a treatment history, current medicines, implant information, and a recent Y-BOCS score. The decision should match the exact device, evidence, safety screen, cost, and your goals.

Medical education and safety note: This is education, not medical advice. It cannot diagnose OCD or decide whether TMS is safe for you. If you may act on thoughts of suicide or cannot stay safe, call emergency services or the U.S. Suicide & Crisis Lifeline at 988 now. More crisis resources are listed at the end of this page.

References

1. National Institute of Mental Health. Obsessive-Compulsive Disorder: When Unwanted Thoughts or Repetitive Behaviors Take Over. NIMH; accessed August 20, 2026.
2. International OCD Foundation. Transcranial Magnetic Stimulation (TMS) for OCD. IOCDF; accessed August 20, 2026.
3. U.S. Food and Drug Administration. De Novo Classification Request for BrainsWay Deep Transcranial Magnetic Stimulation System, DEN170078. Request received September 29, 2017; decision granted August 17, 2018.
4. U.S. Food and Drug Administration. DEN170078 De Novo Classification Request Review Memorandum. The summary header calls September 29, 2017 the “Date of De Novo”; the FDA database identifies that date as receipt and August 17, 2018 as the granted decision.
5. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry. 2019;176(11):931-938. doi:10.1176/appi.ajp.2019.18101180. PMID: 31109199. Trial: NCT02229903.
6. Bello D, et al. Symptom Provocation and Clinical Response to Transcranial Magnetic Stimulation: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82(8):768-777. doi:10.1001/jamapsychiatry.2025.0792. PMID: 40465306. Corrected 2025.
7. Shephard E, Stern ER, van den Heuvel OA, et al. Toward a Neurocircuit-Based Taxonomy to Guide Treatment of Obsessive-Compulsive Disorder. Molecular Psychiatry. 2021;26:4583-4604. doi:10.1038/s41380-020-01007-8. PMID: 33414496. PMCID: PMC8260628.
8. U.S. Food and Drug Administration. MagVenture TMS Therapy for Adjunctive Treatment of OCD, K193006. 510(k) summary; decision August 9, 2020.
9. U.S. Food and Drug Administration. CloudTMS, K221129. 510(k) summary; decision March 10, 2023.
10. U.S. Food and Drug Administration. MagVenture TMS Therapy, K251119. 510(k) summary; decision August 8, 2025.
11. U.S. Food and Drug Administration. Nexstim NBS 6 System, K253098. 510(k) summary; decision March 20, 2026.
12. U.S. Food and Drug Administration. BrainsWay Deep TMS System, K183303. 510(k) database record; decision March 8, 2019.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.